Mon panier

Complement C5a

Complement C5a Informations sur la molécule

Nom anglaisComplement C5aNombre de médicaments commercialisés1
Nombre de médicaments cliniques2Alias de la cibleC5a Complement,Complement 5a,Complement Component 5a
Phase de R&D la plus avancéeApproved
Nom anglaisComplement C5a
Alias de la cibleC5a Complement,Complement 5a,Complement Component 5a
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques2
Phase de R&D la plus avancéeApproved

Complement C5a Liste de produits

  • Attribut

    Protein (6)Kits (1)

  • Bibliothèque de produits

    En ligne (7)

  • Espèces

    Human (3)Mouse (2)Cynomolgus (2)

  • Étiquette

    Tag Free (2)His Tag (3)Fc Tag (1)- (1)

  • Marqueur

    Unconjugated (6)- (1)

Complement C5aContexte de la molécule

Complement component C5a (C5a) is a protein fragment generated upon cleavage of complement component C5. It is a potent chemotactic factor for human peripheral blood neutrophils and monocytes and is believed to play an important role in a number of inflammatory conditions. The major functions of C5a are as follows: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is an effective leukocyte chemoattractant, promoting the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing integrin avidity and upregulating the lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator and appears to be a key factor in the pathogenesis of many inflammatory diseases involving the complement system; and C5a modulates the balance between activating and inhibitory IgG Fc receptors on leukocytes, a mechanism that may enhance autoimmune responses under pathological conditions.

Complement C5aAlias de la molécule

C5a,Complement Component 5a

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
BDB-001BDB-1; BDB-001; BDB001; BDB 001Phase 2 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa
Details
STSA-1002STSA-1002; STSA1002Phase 2 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
VilobelimabIFX-1; CaCP-29ApprovedInflarx NvGohibicEURespiratory Distress Syndrome, AdultInflarx Nv, Inflarx Gmbh2025-01-13Granulomatosis with Polyangiitis; Drug-Related Side Effects and Adverse Reactions; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Shock, Septic; Microscopic Polyangiitis; Pyoderma Gangrenosum; Coronavirus Disease 2019 (COVID-19); Sepsis; Respiratory Distress Syndrome, Adult; Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome
Details

Avis sur les produits

  • 1***52019-09-26
    0Mettre un like
    I have ordered a lot of proteins from Acro. This one especially impressed me. Not only that they generously sent me the trial for my pre-experiment, but also they would develop different species of proteins that I need, which saved me a lot of time. Most importantly, ACRO not only does binding experiments, but also tests related functional assay. They even share them with customers. It is quite comprehensive. May all proteins come from you, ACRO.
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Avis sur les produits
  • Informations sur les médicaments cliniques